N-{2-[(3-bromophenyl)carbonyl]-4,5-dimethoxyphenyl}-2.2-dimethylpropanamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-{2-[(3-bromophenyl)carbonyl]-4,5-dimethoxyphenyl}-2.2-dimethylpropanamide
• 英文别名: N-{2-[(3-bromophenyl)carbonyl]-4,5-dimethoxyphenyl}-2,2-dimethylpropanamide；N-[2-(3-bromobenzoyl)-4,5-dimethoxyphenyl]-2,2-dimethylpropanamide
• 化学式: C₂₀H₂₂BrNO₄
• 分子量: 420.303
• InChiKey: ATMKHUMOKFKLSV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  26
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  64.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-{2-[(3-bromophenyl)carbonyl]-4,5-dimethoxyphenyl}-2.2-dimethylpropanamide 在 盐酸 作用下， 以 1,4-二氧六环 为溶剂， 反应 2.0h， 生成 (2-amino-4,5-dimethoxyphenyl)(3-bromophenyl)methanone
  参考文献：
  名称：

  QUINOLINONE PDE2 INHIBITORS

  摘要：

  公开号：

  EP2456440B1
• 作为产物：
  描述：

  2-溴-4,5-二乙氧基苯胺 在 正丁基锂 、 甲基叔丁基醚 、 sodium hydroxide 作用下， 以 四氢呋喃 为溶剂， 反应 5.0h， 生成 N-{2-[(3-bromophenyl)carbonyl]-4,5-dimethoxyphenyl}-2.2-dimethylpropanamide
  参考文献：
  名称：

  QUINOLINONE PDE2 INHIBITORS

  摘要：

  公开号：

  EP2456440B1

文献信息

• Quinolinone PDE2 Inhibitors
  申请人：De Leon Pablo

  公开号：US20120115885A1

  公开（公告）日：2012-05-10

  The present invention is directed to quinolinone compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

  本发明涉及喹啉酮化合物，其作为治疗与磷酸二酯酶2（PDE2）相关的中枢神经系统疾病的治疗剂。本发明还涉及使用这种化合物治疗神经和精神障碍，例如精神分裂症、精神病或亨廷顿病，以及与纹状体低功能或基底节功能障碍相关的疾病。
• Quinolinone PDE2 inhibitors
  申请人：DeLeon Pablo

  公开号：US08680116B2

  公开（公告）日：2014-03-25

  The present invention is directed to quinolinone compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

  本发明涉及喹啉酮化合物，可用作治疗与磷酸二酯酶2（PDE2）相关的中枢神经系统疾病的治疗剂。本发明还涉及使用这种化合物治疗神经系统和精神障碍，如精神分裂症、精神病或亨廷顿病，以及与纹状体功能减退或基底节功能障碍相关的疾病。
• US8680116B2
  申请人：——

  公开号：US8680116B2

  公开（公告）日：2014-03-25
• [EN] QUINOLINONE PDE2 INHIBITORS<br/>[FR] INHIBITEURS DE QUINOLÉINONE PDE2
  申请人：MERCK SHARP & DOHME

  公开号：WO2011011312A1

  公开（公告）日：2011-01-27

  The present invention is directed to quinolinone compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.